Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years. A ...

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Nutex Health Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Blue Orca Capital issued a short report alleging that Nutex faces litigation risk due to its relationship with HaloMD, which is involved in a fraudulent scheme against insurance companies [2] - Following the release of the Blue Orca report, Nutex's stock price dropped by $11.18 per share, a decrease of 10.05%, closing at $100.01 per share on July 22, 2025 [3] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud [4]

Core Viewpoint - Encompass Health Corporation is under investigation for potential securities fraud and unlawful business practices following allegations of poor performance in safety measures at its facilities, leading to a significant drop in stock price [1][2][3]. Group 1: Investigation and Allegations - Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation regarding possible securities fraud or unlawful business practices [1]. - The New York Times reported that Encompass's for-profit hospitals perform below average on key safety measures, with 34 facilities rated by Medicare as having significantly worse rates of preventable readmissions [2]. Group 2: Stock Price Impact - Following the publication of the allegations, Encompass's stock price fell by $12.39 per share, representing a 10.35% decrease, closing at $107.28 per share on July 15, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Developments - On July 22, 2025, Telix disclosed that it received a subpoena from the U.S. Securities and Exchange Commission, which is seeking various documents and information related to the company's disclosures about its prostate cancer therapeutic candidates [2]. - Following the news of the subpoena, Telix's American Depositary Receipt (ADR) price fell by $1.70, or 10.44%, closing at $14.58 per ADR on July 23, 2025 [2]. Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, having a long history of fighting for the rights of victims of securities fraud and corporate misconduct [3].

Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. concerning allegations of securities fraud and unlawful business practices [2][3]. Group 1: Financial Performance - Fiserv reported Clover gross payment volume (GPV) growth of only 8% for Q1 2025, a significant decline from the 14% to 17% growth rates observed in 2024 [3]. - The company attributed the slowdown in growth to reduced transaction volumes from merchants transitioning from the older Payeezy platform to the newer Clover platform [3]. - On July 23, 2025, Fiserv lowered the top end of its full-year organic growth guidance and confirmed that quarterly organic revenue in the Merchant segment decelerated to 9% year-over-year from 11% in the previous quarter [5]. Group 2: Stock Price Impact - Following the Q1 2025 report, Fiserv's stock price fell by $40.20 per share, or 18.52%, closing at $176.90 on April 24, 2025 [4]. - On May 15, 2025, after disclosing continued GPV growth deceleration, the stock price dropped by $30.73 per share, or 16.19%, closing at $159.13 [4]. - After the July 23 announcement regarding lowered growth guidance, Fiserv's stock price fell by $22.90 per share, or 13.85%, closing at $143.00 [5].

Core Viewpoint - Dow Inc. is under investigation for potential securities fraud and unlawful business practices following a significant decline in its financial performance and stock price [1][2]. Financial Performance - For Q2 2025, Dow reported net sales of $10.1 billion, a decrease of 7% year-over-year, with declines observed across all operating segments [2]. - Sequentially, net sales fell by 3%, with seasonally higher demand in Performance Materials & Coatings being offset by declines in other segments [2]. - Following the financial results announcement, Dow's stock price dropped by $5.30 per share, or 17.45%, closing at $25.07 per share on July 24, 2025 [2]. Corporate Actions - Dow's CEO announced adjustments to the company's dividend to maintain a balanced capital allocation framework [2].

Core Insights - Simulations Plus is under investigation for potential securities fraud and unlawful business practices [1] - The company reported third fiscal quarter sales of $20.4 million, missing the consensus estimate of $20.9 million, and incurred a net loss of $67.3 million, including a non-cash impairment charge of $77.2 million [2] - Following the financial report, Simulations Plus's stock price dropped by $4.50, or 25.76%, closing at $12.97 per share [3] - The company revised its fiscal 2025 adjusted earnings guidance down to $0.93 to $1.06 from a previous range of $1.07 to $1.20 [2] - A restructuring initiative was initiated in June, involving workforce reductions and cost-cutting measures to enhance operational efficiency [2]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against Fiserv, Inc. for alleged misleading statements and failures to disclose critical information regarding its Clover platform and Payeezy merchants during the Class Period from July 24, 2024, to July 23, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Fiserv made false statements about its Clover platform's growth and business prospects, which were misleading to investors [5]. - Allegations include that Fiserv forced Payeezy merchants to migrate to Clover, which temporarily inflated Clover's revenue growth and gross payment volume (GPV) [5]. - The lawsuit states that many former Payeezy merchants switched to competitors due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's GPV growth [5]. Group 2: Investor Participation - Investors who purchased Fiserv common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can submit a form or contact the law firm for more information [3][6]. - A lead plaintiff is needed to represent other class members, and interested parties must move the Court by September 22, 2025 [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

BENSALEM, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to howardsmith@howardsmithla ...

Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims against RxSight, Inc. for misleading statements regarding its business and financial performance during the specified Class Period [1][4]. Company Background - RxSight, Inc. is a commercial-stage medical technology company that specializes in the research, development, manufacturing, and marketing of light-adjustable intraocular lenses (LAL) used in cataract surgery [3]. Securities Fraud Claims - The class action complaint alleges that RxSight made materially false and misleading statements, failing to disclose declines in product sales and utilization, and overstating demand for its intraocular lens products [4]. - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [4]. Financial Performance - On July 9, 2025, RxSight reported significant declines in sales of its Light Delivery Device (LDD), usage of its light-adjustable intraocular lenses (LALs), and total revenue, leading to a reduction in its Full Year 2025 guidance by approximately $42.5 million [5]. - Following this disclosure, RxSight's stock price fell by $4.84 per share, or 37.8%, closing at $7.95 per share on July 9, 2025 [5].